Form 4: Blueprint Medicines CEO Kate Haviland Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
CEO Kate Haviland sold shares of Blueprint Medicines to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On March 5, 2025, Kate Haviland, CEO of Blueprint Medicines Corp, sold 16,151 shares of common stock at a price of $88.8 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Haviland directly owns 168,427 shares of Blueprint Medicines Corp.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock sales for tax purposes, so the sentiment is neutral.
Industry Context
Form 4 filings are a routine part of insider trading activity and are required by the SEC to provide transparency into the transactions of company executives and directors. This transaction appears to be a standard 'sell to cover' to meet tax obligations, which is a common practice.
Stakeholder Impact
- The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although it is a common practice to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Date of stock sale transaction |
| 03/06/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.